Product Description
Beloranib is a fumagillin analogue and inhibitor of methionineaminopeptidase 2 (METAP2), with potential antiangiogenic and anti-obesity activity. As an irreversible inhibitor, beloranib blocks METAP2's functions, which include both protecting eukaryotic initiation factor 2 from inhibitory phosphorylation during translation, and by removing the amino-terminal methionine residue from nascent protein permitting the conversion of an inactive or non-functional protein to an active one. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Beloranib)
Mechanisms of Action: METAP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Zafgen, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Prader-Willi Syndrome|Overweight|Hyperphagia|Obesity
Phase 2: Type 2 Diabetes|Obesity|Adamantinoma|Overweight|Craniopharyngioma|Prader-Willi Syndrome
Phase 1: Obesity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01507077 |
ZAF-101 | P1 |
Completed |
Obesity |
2012-03-01 |
2019-03-19 |
Treatments |
|
NCT01372761 |
ZAF-003AUS | P1 |
Completed |
Obesity |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT01028261 |
ZAF-001 | P1 |
Completed |
Obesity |
2010-10-01 |
2019-03-19 |
Treatments |
|
NCT02324491 |
ZAF-203 | P2 |
Terminated |
Obesity|Type 2 Diabetes |
2015-12-01 |
2019-03-20 |
Treatments |
|
NCT02063295 |
ZAF-221 | P2 |
Completed |
Overweight|Obesity|Craniopharyngioma|Adamantinoma |
2014-11-01 |
2019-03-20 |
Treatments |
|
NCT01818921 |
ZAF-211 | P2 |
Completed |
Obesity|Prader-Willi Syndrome|Overweight |
2013-11-01 |
2019-03-19 |
Treatments |
|
NCT01666691 |
ZAF-201 | P2 |
Completed |
Obesity |
2013-05-01 |
2019-03-19 |
Treatments |
|
2015-000660-33 |
bestPWS II | P3 |
Terminated |
Prader-Willi Syndrome|Overweight|Hyperphagia |
2017-08-30 |
2022-03-13 |
Treatments |
|
NCT02179151 |
bestPWS | P3 |
Terminated |
Prader-Willi Syndrome|Obesity |
2015-12-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/22/2020 |
News Article |
Methionine Aminopeptidase 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com |
|
10/17/2019 |
News Article |
Inversago Pharma Strengthens its Board of Directors with the Appointment of Two Industry Experts |
|
09/05/2019 |
News Article |
Zafgen to Explore Strategic Alternatives |
|
07/24/2019 |
News Article |
Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061 |